SRX2565572 GSM2492500 SRP100018 SRS1982054 GSM2492500 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492500 GEO Accession GSM2492500 SRX2565573 GSM2492501 SRP100018 SRS1982055 GSM2492501 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492501 GEO Accession GSM2492501 SRX2565574 GSM2492502 SRP100018 SRS1982057 GSM2492502 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492502 GEO Accession GSM2492502 SRX2565575 GSM2492503 SRP100018 SRS1982056 GSM2492503 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492503 GEO Accession GSM2492503 SRX2565576 GSM2492504 SRP100018 SRS1982058 GSM2492504 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492504 GEO Accession GSM2492504 SRX2565577 GSM2492505 SRP100018 SRS1982059 GSM2492505 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492505 GEO Accession GSM2492505 SRX2565578 GSM2492506 SRP100018 SRS1982060 GSM2492506 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492506 GEO Accession GSM2492506 SRX2565579 GSM2492507 SRP100018 SRS1982061 GSM2492507 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492507 GEO Accession GSM2492507 SRX2565580 GSM2492508 SRP100018 SRS1982062 GSM2492508 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492508 GEO Accession GSM2492508 SRX2565581 GSM2492509 SRP100018 SRS1982063 GSM2492509 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492509 GEO Accession GSM2492509 SRX2565582 GSM2492510 SRP100018 SRS1982064 GSM2492510 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492510 GEO Accession GSM2492510 SRX2565583 GSM2492511 SRP100018 SRS1982065 GSM2492511 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492511 GEO Accession GSM2492511 SRX2565584 GSM2492512 SRP100018 SRS1982066 GSM2492512 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492512 GEO Accession GSM2492512 SRX2565585 GSM2492513 SRP100018 SRS1982067 GSM2492513 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492513 GEO Accession GSM2492513 SRX2565586 GSM2492514 SRP100018 SRS1982069 GSM2492514 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492514 GEO Accession GSM2492514 SRX2565587 GSM2492515 SRP100018 SRS1982068 GSM2492515 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492515 GEO Accession GSM2492515 SRX2565588 GSM2492516 SRP100018 SRS1982070 GSM2492516 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492516 GEO Accession GSM2492516 SRX2565589 GSM2492517 SRP100018 SRS1982072 GSM2492517 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492517 GEO Accession GSM2492517 SRX2565590 GSM2492518 SRP100018 SRS1982071 GSM2492518 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492518 GEO Accession GSM2492518 SRX2565591 GSM2492519 SRP100018 SRS1982073 GSM2492519 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492519 GEO Accession GSM2492519 SRX2565592 GSM2492520 SRP100018 SRS1982074 GSM2492520 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492520 GEO Accession GSM2492520 SRX2565593 GSM2492521 SRP100018 SRS1982075 GSM2492521 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492521 GEO Accession GSM2492521 SRX2565594 GSM2492522 SRP100018 SRS1982076 GSM2492522 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492522 GEO Accession GSM2492522 SRX2565595 GSM2492523 SRP100018 SRS1982078 GSM2492523 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492523 GEO Accession GSM2492523 SRX2565596 GSM2492524 SRP100018 SRS1982077 GSM2492524 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492524 GEO Accession GSM2492524 SRX2565597 GSM2492525 SRP100018 SRS1982079 GSM2492525 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492525 GEO Accession GSM2492525 SRX2565598 GSM2492526 SRP100018 SRS1982081 GSM2492526 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492526 GEO Accession GSM2492526 SRX2565599 GSM2492527 SRP100018 SRS1982082 GSM2492527 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492527 GEO Accession GSM2492527 SRX2565600 GSM2492528 SRP100018 SRS1982080 GSM2492528 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492528 GEO Accession GSM2492528 SRX2565601 GSM2492529 SRP100018 SRS1982083 GSM2492529 RNA-Seq TRANSCRIPTOMIC cDNA CD3+CD4+ and CD3+CD8+ TEM (CD45RA-CCR7-) cells were sorted into CD69+ and CD69- subsets based on the gating strategy in Fig. S1, from spleen and lung tissue of three individual donors (D226, D233, D250, see Table S4), and CD4+ and CD8+ TEM cells were sorted from peripheral blood using the BD-influx sorter. RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), and RNA concentration and quality was assessed using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA was submitted for sequencing standard Truseq with poly-A pulldown Illumina HiSeq 2500 gds 302492529 GEO Accession GSM2492529